Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 10/20 | 0.58 |
| ▸ | NPC1 | O15118 | 9/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17221244 | 0.83 | KDM4E (0.63) | KDM4ETP53RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL8814958 | 0.83 | KDM4E (0.68) | KDM4ETP53RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL9598420 | 0.83 | KDM4E (0.63) | KDM4ETP53RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL9570213 | 0.83 | KDM4E (0.63) | KDM4ETP53RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL13059011 | 0.83 | KDM4E (0.63) | KDM4ETP53RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL8174291 | 0.81 | NPC1 (0.50) | KDM4ETP53RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL16797813 | 0.80 | KDM4E (0.59) | KDM4ETP53RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL16797803 | 0.80 | KDM4E (0.59) | KDM4ETP53RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5760557 | 0.79 | PIK3CG (0.55) | KDM4ETP53RAB9ANPC1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL22499245 | 0.79 | NPC1 (0.49) | KDM4ETP53RAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388577-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2025-12-25 | — | — | US | disclosed |
| US-12358915-B2 | METTL3 inhibitory compounds | STORM Therapeutics Ltd. (GB) | 2025-07-15 | — | — | US | disclosed |
| US-20230085408-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LIMITED (GB) | 2023-03-16 | — | — | US | disclosed |
| US-20220144840-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF AMYLOID-RELATED DISEASES | D. E. SHAW RESEARCH, LLC | 2022-05-12 | — | — | US | disclosed |
| US-20220144840-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF AMYLOID-RELATED DISEASES | D. E. SHAW RESEARCH, LLC | 2022-05-12 | — | — | US | disclosed |
| EP-3946618-A1 | METTL3 INHIBITORY COMPOUNDS | Storm Therapeutics Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020201773-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020201773-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020167567-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF AMYLOID-RELATED DISEASES | D.E. SHAW RESEARCH, LLC (US) | 2020-08-20 | — | — | WO | disclosed |
| EP-2875026-B1 | IMIDAZOPYRIDINE DERIVATIVE USED IN THE TREATMENT OF DIABETES | METABRAIN RES (FR) | 2016-09-21 | — | — | EP | disclosed |
| EP-2427454-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | Envivo Pharmaceuticals, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20100292238-A1 | Phenoxymethyl Heterocyclic Compounds | FMR LLC | 2010-11-18 | — | — | US | disclosed |
| US-20100292238-A1 | Phenoxymethyl Heterocyclic Compounds | FMR LLC | 2010-11-18 | — | — | US | disclosed |
| US-20100292238-A1 | Phenoxymethyl Heterocyclic Compounds | FMR LLC | 2010-11-18 | — | — | US | disclosed |
| WO-2010128995-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010128995-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-6013654-A | Imidazo[1,2-A]pyridines for the treatment of CNS and cardiac diseases | PHARMACIA & UPJOHN COMPANY (US) | 2000-01-11 | — | — | US | disclosed |
| US-5912246-A | Imidazo 1,2-a!pyridines for the treatment of CNS and cardiac diseases | PHARMACIA & UPJOHN COMPANY (US) | 1999-06-15 | — | — | US | disclosed |
| EP-0809642-A1 | IMIDAZO 1,2-A]PYRIDINES FOR THE TREATMENT OF CNS AND CARDIAC DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 1997-12-03 | — | — | EP | disclosed |
| WO-1996025414-A1 | IMIDAZO[1,2-A]PYRIDINES FOR THE TREATMENT OF CNS AND CARDIAC DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 1996-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358915-B2 | METTL3 inhibitory compounds | METTL3, METTL16, DIMT1 | KDM4E 62/4885TP53 887/4885RAB9A 1839/4885 |
| US-20250388577-A1 | METTL3 INHIBITORY COMPOUNDS | METTL3, RNMT, TPMT | KDM4E 717/4885TP53 2077/4885RAB9A 1986/4885 |
| US-20100292238-A1 | Phenoxymethyl Heterocyclic Compounds | PDE3A, PDE2A, PDE5A | KDM4E 559/4885TP53 4831/4885RAB9A 1008/4885 |
| US-20220144840-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF AMYLOID-RELATED DISEASES | APP, PSEN1, BACE1 | KDM4E 4064/4885TP53 713/4885RAB9A 1350/4885 |
| US-20230085408-A1 | METTL3 INHIBITORY COMPOUNDS | METTL3, METTL16, DIMT1 | KDM4E 62/4885TP53 887/4885RAB9A 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.